Enanta Pharmaceuticals Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Enanta Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ENTA, but not buy additional shares or sell existing shares.
View analyst ratings for Enanta Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Enanta Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Enanta Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Enanta Pharmaceuticals.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.94) by $0.15. The biotechnology company earned $20.10 million during the quarter, compared to analyst estimates of $25.05 million. Enanta Pharmaceuticals had a negative net margin of 78.57% and a negative trailing twelve-month return on equity of 12.21%. The business's quarterly revenue was down 27.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.30) EPS.
View Enanta Pharmaceuticals' earnings history.

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ENTA stock has decreased by 13.6% and is now trading at $45.74.
View which stocks have been most impacted by COVID-19.

7 equities research analysts have issued 12 month price objectives for Enanta Pharmaceuticals' shares. Their forecasts range from $30.00 to $107.00. On average, they expect Enanta Pharmaceuticals' share price to reach $65.29 in the next year. This suggests a possible upside of 42.7% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals or view top-rated stocks among Wall Street analysts.

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Enanta Pharmaceuticals include Intra-Cellular Therapies (ITCI), Sage Therapeutics (SAGE), Emergent BioSolutions (EBS), Cassava Sciences (SAVA), PTC Therapeutics (PTCT), Nektar Therapeutics (NKTR), Insmed (INSM), Taro Pharmaceutical Industries (TARO), Dicerna Pharmaceuticals (DRNA), Cryoport (CYRX), Rocket Pharmaceuticals (RCKT), IGM Biosciences (IGMS), Amicus Therapeutics (FOLD), Pacira BioSciences (PCRX) and Corcept Therapeutics (CORT).
View all of ENTA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (18.49%), Armistice Capital LLC (8.16%), Renaissance Technologies LLC (4.46%), Price T Rowe Associates Inc. MD (4.28%), Krensavage Asset Management LLC (4.27%) and Northern Trust Corp (3.20%).
View institutional ownership trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, Dimensional Fund Advisors LP, Federated Hermes Inc., AQR Capital Management LLC, Goldman Sachs Group Inc., and Tudor Investment Corp Et Al.
View insider buying and selling activity for Enanta Pharmaceuticals or view top insider-selling stocks.

ENTA stock was acquired by a variety of institutional investors in the last quarter, including Northern Trust Corp, BlackRock Inc., Armistice Capital LLC, Hennion & Walsh Asset Management Inc., Geode Capital Management LLC, UBS Group AG, Rafferty Asset Management LLC, and Jackson Creek Investment Advisors LLC.
View insider buying and selling activity for Enanta Pharmaceuticals or or view top insider-buying stocks.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTA stock can currently be purchased for approximately $45.74.

Enanta Pharmaceuticals has a market capitalization of $923.72 million and generates $122.47 million in revenue each year. The biotechnology company earns $-36,170,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis.

Enanta Pharmaceuticals employs 141 workers across the globe.

The official website for Enanta Pharmaceuticals is www.enanta.com.

Enanta Pharmaceuticals is headquartered at 500 ARSENAL STREET, WATERTOWN MA, 02472.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]